Login
$MAZE
$33.58 -$0.75 (2.18%) Live

Company Executives

Officer Age In this role Source
Jason Coloma Also a director
Chief Executive Officer and Director
50 Not stated
Misbah Tahir
Chief Financial Officer
51 Since 2025
1 year
Harold S. Bernstein
President, R&D & CMO
Title from the Form 4 dated Oct 1, 2026
66 Not stated
Courtney Phillips
General Counsel and Corporate Secretary
51 Since 2024
2 years
Atul Dandekar
CSBO
Title from the Form 4 dated Oct 29, 2026
55 Not stated

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 28, 2026 · updated by the 8-K of Aug 17, 2026

Directors
12
serving now
Independent
0 of 2
stated in the proxy; 10 not stated
Average tenure
5.1 years
from year joined
CEO also chairs the board
No
Hervé Hoppenot
Director On board Independent Committees Other public boards 2025 pay Source
Hervé Hoppenot
2025
1 year
Not stated
Nominating and Corporate Governance Committee · Chair
None stated $738,726
Jason Coloma
2019
7 years
Not independent None stated None stated Paid as CEO
Neil Kumar
2026
this year
Not stated
Audit Committee
None stated Not stated
Jonathan Lim
2019
7 years
Not stated None stated None stated $344,240
Richard Scheller
2019
7 years
Not stated None stated None stated Not stated
Nancy C. Andrews
2021
5 years
Not stated None stated None stated Not stated
Charles Homcy
2018
8 years
Not independent None stated None stated $602,065
Daniel Spiegelman
2020
6 years
Not stated None stated Spruce Biosciences, Inc., vTv Therapeutics Inc. $348,983
Paula A. Johnson Joined Aug 13, 2026
- -
nominating and corporate governance committee
- -
Sophie Kornowski Joined Aug 13, 2026
- -
audit committee compensation committee
- -
Neil Exter Leaving at the meeting
Not stated Not stated None stated None stated $488,674
Catherine Angell Sohn Leaving at the meeting
Not stated Not stated None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

5 disclosed in the proxy filed Apr 28, 2026
Charles Homcy, M.D.
a member of our board of directors
$240,000 per year

Consulting agreement under which the company pays Dr. Homcy for consulting services.

Charles Homcy, M.D.
Amount not stated
2024

Option to purchase 46,675 shares of common stock granted as additional consideration for consulting services.

Charles Homcy, M.D.
Amount not stated
2024

Additional option to purchase 45,638 shares of common stock granted as additional consideration for consulting services.

entities with which certain of our directors are affiliated
hold more than 5% of our outstanding capital stock
Amount not stated

Investors' Rights Agreement with certain stockholders, including director-affiliated entities holding more than 5%, granting registration rights.

each of our directors and executive officers
directors and executive officers of the company
Amount not stated

Indemnification agreements with each director and executive officer, requiring indemnification and advancement of expenses.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support